2025 Archive
12 articles from 2025
FDA adopts agentic artificial intelligence in latest push to infuse AI into agency
TITLE: FDA Implements Agentic AI for Internal Operations: Implications for Regulatory Processes SUMMARY: The U.S. Food and Drug Administration (FDA) is advancing its integration of artificial intellig...
Adjuvant Docetaxel Versus Surveillance in Intermediate- or High-risk Prostate Cancer After Radical Curative Radiotherapy: Final Survival Results from the SPCG-13 Trial
TITLE: Adjuvant Docetaxel vs. Surveillance for Intermediate/High-Risk Prostate Cancer Post-Radiotherapy: SPCG-13 Final Survival Results SUMMARY: The SPCG-13 trial's final survival results investigated...
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial
TITLE: Niraparib/Abiraterone/Prednisone in mCRPC: Final OS Data from MAGNITUDE Trial SUMMARY: The final overall survival (OS) analysis from the Phase 3 MAGNITUDE trial investigated the combination of ...
GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement
TITLE: Legal Dispute Emerges Between GSK's Tesaro and AnaptysBio Over PD-1 Inhibitor Jemperli (Dostarlimab) SUMMARY: A significant legal conflict has developed between GlaxoSmithKline's (GSK) subsidia...
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia
TITLE: FDA Approves Imetelstat for Transfusion-Dependent Anemia in Low- to Intermediate-Risk MDS SUMMARY: The US Food and Drug Administration (FDA) has approved imetelstat, a first-in-class telomerase...
Lowering Blood Pressure, Raising Cancer Risk?: Evidence From Randomized Clinical Trials and Genetic Studies
TITLE: Antihypertensive Therapy and Malignancy Risk: Analyzing Evidence from RCTs and Genetic Studies SUMMARY: This study published in *JACC: CardioOncology* investigates the complex relationship betw...
Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer
TITLE: Survival Outcomes of Neoadjuvant Chemotherapy in Advanced Non-Serous Ovarian Cancer SUMMARY: This study, published in *Gynecologic Oncology*, investigates the survival impact of neoadjuvant che...
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
TITLE: HER2CLIMB-02 Analysis: Tucatinib Plus T-DM1 for HER2-Positive Metastatic Breast Cancer SUMMARY: The Phase III HER2CLIMB-02 clinical trial evaluated the efficacy and safety of adding the tyrosin...
Impact of Industry Collaboration on US Food and Drug Administration Approval Success in Genitourinary Malignancy Phase III Clinical Trials
TITLE: Industry Collaboration and FDA Approval Success in Genitourinary Malignancy Phase III Trials SUMMARY: A recent analysis published in *JCO Oncology Practice* investigates the relationship betwee...
ROME trial Wasn't Built in a Day: The Decade-Long Journey to Randomized Evidence in Precision Oncology
TITLE: ROME Trial Analysis: The Evolution of Randomized Evidence in Precision Oncology SUMMARY: This commentary in *Annals of Oncology* explores the critical transition from early-phase, single-arm st...
Locally advanced cervical cancer and para-aortic lymphadenectomy: impact of the number of removed lymph nodes, a FRANCOGYN group study
TITLE: Para-aortic Lymphadenectomy in Locally Advanced Cervical Cancer: Impact of Lymph Node Yield (FRANCOGYN Study) SUMMARY: This publication from the European Journal of Surgical Oncology presents f...
Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study
TITLE: Eftilagimod Alpha and Pembrolizumab in First-Line Metastatic NSCLC: TACTI-002 Study Analysis SUMMARY: Recent data published in *JCO Oncology Advances* presents findings from the TACTI-002 study...
